Identification of Novel Immunotherapy Targets in Myeloma

RNA sequencing (RNA-Seq) was performed on 94 multiple myeloma (MM) patient samples. We used genomic subgroup and high-risk markers to identify therapeutic targets, including TNFRSF17, GPRC5D, ITGA4, and LAX1, with low predicted toxicity and high specificity to MM and genomic subgroups such as those with TP53 alterations.]]>
Samples were taken from the Indiana Myeloma Registry where bone marrow aspirates from myeloma patients had been CD138+ magnetic assisted cell sorting. Samples required to have >70% purity for CD138 and sufficient cells for DNA and RNA extraction (>500,000 cells).]]>